Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
BMC Cancer|December 17, 2022
Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1Ou Yamaguchi, Kazuyuki Atarashi, Kenichi Yoshimura, et al.
Cancer Medicine|June 14, 2022
Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancerAyako Shiono, Hisao Imai, Satoshi Wasamoto, et al.
Investigational New Drugs|June 24, 2022
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancerHisao Imai, Yoshiaki Nagai, Hiroyuki Minemura, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2023
Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study)Atsushi Nakamura, Ou Yamaguchi, Keita Mori, et al.
Scientific Reports|February 15, 2024
Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051Keita Miura, Ou Yamaguchi, Keita Mori, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 14, 2020
Real-World Evaluation of Factors for Interstitial Lung Disease Incidence and Radiologic Characteristics in Patients With EGFR T790M-positive NSCLC Treated With Osimertinib in JapanAkihiko Gemma, Masahiko Kusumoto, Fumikazu Sakai, et al.
Journal of Cancer Research and Clinical Oncology|December 20, 2019
Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancerHisao Imai, Satoshi Wasamoto, Ou Yamaguchi, et al.
Thoracic Cancer|November 28, 2023
Extended ICI treatment after first-line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non-small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study)Ou Yamaguchi, Keita Mori, Saori Takata, et al.
JTO Clinical and Research Reports|May 6, 2024
Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060Takehiro Tozuka, Yuji Minegishi, Ou Yamaguchi, et al.
Cancer Chemotherapy and Pharmacology|March 21, 2020
Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancerOu Yamaguchi, Hisao Imai, Hiroyuki Minemura, et al.
Pageof 10